COMP <GO>
EFOR vs ASTH // RETURN ON INVESTED CAPITAL (ROIC)
Everforth Inc. (NYSE) VS. Astrana Health Inc. (NASDAQ) • 15-METRIC TALLY: EFOR 8
— ASTH 4
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: EFOR
LAST: $37.50 (-1.78%) • MKT CAP: $1.57B
roic
6.50%
LAST: $36.88 (+0.96%) • MKT CAP: $1.81B
roic
4.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EFOR VS. ASTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EFOR | ASTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 6.50% | 4.60% | +1.90 | EFOR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.6x | 27.3x | -17.70 | EFOR | /valuation <GO> |
| Free Cash Flow Yield | 18.99% | 5.75% | +13.24 | EFOR | /fcf-yield <GO> |
| Operating Margin | 5.80% | 2.50% | +3.30 | EFOR | /operating-margins <GO> |
| Net Profit Margin | 2.90% | 0.80% | +2.10 | EFOR | /net-margins <GO> |
| Revenue Growth (YoY) | -2.90% | 56.40% | -59.30 | ASTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.43% | -0.43 | ASTH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.35 | 2.54 | -0.19 | ASTH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 6/9 | +1.00 | EFOR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.4 | 46.8 | +5.60 | EFOR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.5x | 63.6x | -51.10 | EFOR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.57B | $1.81B | -$246.7M | ASTH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EFOR REV | ASTH REV | EFOR GROSS % | ASTH GROSS % | EFOR FCF | ASTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.98B | $3.18B | 28.9% | — | $288.1M | $104.5M |
| FY 2024 | $4.10B | $2.03B | 28.9% | — | $364.7M | $44.2M |
| FY 2023 | $4.45B | $1.39B | — | — | $456.9M | $68.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EFOR // BETA —
ASTH // BETA —